THE EMERGING ROLE OF BOTULINUM TOXIN IN THE TREATMENT OF OROFACIAL DISORDERS: LITERATURE UPDATE
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i9.16914Keywords:
Botulinum toxin, Botulinum toxin A, Botox, Orofacial disorders, Temporomandibular disorders, Dentistry, Myofascial painAbstract
Botulinum toxin (BTX) is a lethal neurotoxin produced by Gram-positive anaerobic bacterium called Clostridium botulinum. It is the first toxin used fortherapeutic purposes since 1989. BTX treatment is relatively safe and efficacious, less invasive, conservative, and the effects are faster and reversible.The purpose of this article is to review the literature regarding the applications of BTX in the treatment of various orofacial disorders, their mechanismof action, contraindications, and complications. From the recently published literature, it is clear that the role of BTX as a therapeutic agent for severalconditions is expanding. With the training of BTX-A injection techniques and adequate knowledge about treatment protocols, general dentists cansafely administer BTX injections. The ability to use Botox as an adjuvant and primary mode of the treatment for various maxillofacial disorders offersexciting treatment options for dentists and patients in the future.
Downloads
References
Lu DW, Lippitz J. Complications of botulinum neurotoxin. Dis Mon 2009;55(4):198-211.
Cherington M. Botulism: Update and review. Semin Neurol 2004;24(2):155-63.
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001;285(8):1059-70.
Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38(8):245-58.
Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87(10):1044-9.
Scott AB. Development of botulinum toxin therapy. Dermatol Clin 2004;22(2):131-3, v.
Popoff MR, Bouvet P. Genetic characteristics of toxigenic Clostridia and toxin gene evolution. Toxicon 2013;75(1):63-89.
Melling J, Hambleton P, Shone CC. Clostridium botulinum toxins: Nature and preparation for clinical use. Eye (Lond) 1988;2:16-23.
Bakheit AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf 2006;1(3):271-9.
Schames J, Dov Prero Y, Schames D, Schames M, Gabriel W, Reed R. Uncontrollable distant effects of botulinum neurotoxin injections. J Calif Dent Assoc 2009;37:44-5.
Meunier FA, Schiavo G, Molgó J. Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002;96:105-13.
Blitzer A, Sulica L. Botulinum toxin: Basic science and clinical uses in otolaryngology. Laryngoscope 2001;111(2):218-26.
Kao I, Drachman DB, Price DL. Botulinum toxin: Mechanism of presynaptic blockade. Science 1976;193(4259):1256-8.
Dressler D, Adib Saberi F. Botulinum toxin: Mechanisms of action. Eur Neurol 2005;53(1):3-9.
Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13(1):150-4.
Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246(4):265-74.
Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46(1):26-9.
Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A - Resistant patients. Mov Disord 1996;11:181-4.
Jaspers GW, Pijpe J, Jansma J. The use of botulinum toxin Type A in cosmetic facial procedures. Int J Oral Maxillofac Surg 2011;40(2):127-33.
Hoque A, McAndrew M. Use of botulinum toxin in dentistry. N Y State Dent J 2009;75(6):52-5.
de Maio M. Therapeutic uses of botulinum toxin: From facial palsy to autonomic disorders. Expert Opin Biol Ther 2008;8(6):791-8.
Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: Treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003;29:802-9.
Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: Advantages of combination therapy. Ann Plast Surg 2004;52(5):442-7.
Amin V, Amin V, Swathi D, Jabir DA, Shetty P. Enhancing the smile with botox - Case report. Glob J Med Res 2014;13:15-8.
Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 2008;10(1):35-42.
Pedron IG. Gingival resection surgery complementation through botulinum toxin application at the management of gummy smile. RSBO 2015;12(4):389-93.
Gracco A, Tracey S. Botox and the gummy smile. Prog Orthod 2010;11(1):76-82.
Mangano A, Mangano A. Current strategies in the treatment of gummy smile using botulinum toxin Type A. Plast Reconstr Surg 2012;129(6):1015e.
Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: A new approach based on the gingival exposure area. J Am Acad Dermatol 2010;63(6):1042-51.
Niamtu J 3rd. Botox injections for gummy smiles. Am J Orthod Dentofacial Orthop 2008;133(6):782-3.
Polo M. Botulinum toxin Type A in the treatment of excessive gingival display. Am J Orthod Dentofacial Orthop 2005;127(2):214-8.
Sucupira E, Abramovitz A. A simplified method for smile enhancement: Botulinum toxin injection for gummy smile. Plast Reconstr Surg 2012;130(3):726-8.
Niamtu J 3rd. Botulinum toxin A: A review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003;61(3):317-24.
Makmacher L. Botulinum Toxin Frontline TMJ syndrome and Dental Therapeutic Treatment. ??AQ1 ?: Academy of General Dentistry; 2013.
Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin A. Headache 2002;42(10):1033 7.
Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain 2002;18 6 Suppl: S198-203.
Kim HS, Yun PY, Kim YK. A clinical evaluation of botulinum toxin-a injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg 2016;38(1):5.
Chen YW, Chiu YW, Chen CY, Chuang SK. Botulinum toxin therapy for temporomandibular joint disorders: A systematic review of randomized controlled trials. Int J Oral Maxillofac Surg 2015;44:1018-26.
Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis 2007;13(3):253-60.
Freund B, Schwartz M, Symington JM. The use of botulinium toxin for the treatment of temperomandibular disorders: Preliminary findings. J Oral Maxillofac Surg 1999;57(8):916-20.
Lee KM, Chow J, Hui E, Li W. Botulinum toxin Type A injection for the management of myofascial temporomandibular pain disorder. Asian J Oral Maxillofac Surg 2005;17(2):100 3.
Katz H. Botulinum toxins in dentistry - The new paradigm for masticatory muscle hypertonicity. Singapore Dent J 2005;27(1):7-12.
Zhang LD, Liu Q, Zou DR, Yu LF. Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A(BTX - A)for treatment of temporomandibular disorder. Br J Oral Maxillofac Surg 2016;54(7):736-40.
Park SY, Park YW, Ji YJ, Park SW, Kim SG. Effects of a botulinum toxin Type A injection on the masseter muscle: An animal model study. Maxillofac Plast Reconstr Surg 2015;37:10.
Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: An evidence-based review. Int Dent J 2012;62(1):1-5.
Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: A randomized controlled trial. Am J Phys Med Rehabil 2010;89(1):16-23.
Shim YJ, Lee MK, Kato T, Park HU, Heo K, Kim ST. Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: A polysomnographic evaluation. J Clin Sleep Med 2014;10(3):291-8.
Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry 1990;53(6):530.
Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000;131(2):211-6.
El Maaytah M, Jerjes W, Upile T, Swinson B, Hopper C, Ayliffe P. Bruxism secondary to brain injury treated with botulinum toxin-A: A case report. Head Face Med 2006;2:41.
Ivanhoe CB, Lai JM, Francisco GE. Bruxism after brain injury: Successful treatment with botulinum toxin-A. Arch Phys Med Rehabil 1997;78(11):1272-3.
Ludlow CL, Hallett M, Rhew K, Cole R, Shimizu T, Sakaguchi G, et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992;326(5):349-50.
Bentsianov B, Francis A, Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Oper Tech Otolaryngol Head Neck Surg 2004;15:110 3.
Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin Type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 2003;29(5):484-9.
Al-Ahmad HT, Al-Qudah MA. The treatment of masseter hypertrophy with botulinum toxin Type A. Saudi Med J 2006;27(3):397-400.
Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: Case report. J Oral Maxillofac Surg 1999;57(8):1017-9.
Rijsdijk BA, van ES RJ, Zonneveld FW, Steenks MH, Koole R. Botulinum toxin Type A treatment of cosmetically disturbing masseteric hypertrophy. Ned Tijdschr Geneeskd 1998;142(10):529-32.
Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI. Electrophysiologic change and facial contour following botulinum toxin A injection in square faces. Plast Reconstr Surg 2007;120(3):769-78.
Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin Type A. Br J Oral Maxillofac Surg 1994;32(1):26-8.
Bas B, Ozan B, Muglali M, Celebi N. Treatment of masseteric hypertrophy with botulinum toxin: A report of two cases. Med Oral Patol Oral Cir Bucal 2010;15(4):e649-52.
Isaac AM. Unilateral temporalis muscle hypertrophy managed with botulinum toxin Type A. Br J Oral Maxillofac Surg 2000;38(5):571-2.
Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg 2008;66(2):1644-51.
von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 2003;61(7):774-8.
Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin Type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain 2011;152(9):1988-96.
Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: An evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104(2):e1-11.
Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002;3(1):21-7.
Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin Type A following long-term use. Eur J Neurol 2006;13 Suppl 4:35-40.
Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study. Cranio 2008;26(2):126-35.
Machado E, Santos LZ, Custódio LG, Cunali PA. Botulinum toxin for treating muscular temporomandibular disorders: A systematic review. Dent Press J Orthod 2012;17(6):167-71.
Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting - A review of the literature. Pain Pract 2008;8(4):269-76.
Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev 2014;7:CD007533.
Sidebottom AJ, Patel AA, Amin J. Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg 2013;51(3):199-205.
Cersósimo MG, Bertoti A, Roca CU, Micheli F. Botulinum toxin in a case of hemimasticatory spasm with severe worsening during pregnancy. Clin Neuropharmacol 2004;27(1):6-8.
Auger RG, Litchy WJ, Cascino TL, Ahlskog JE. Hemimasticatory spasm: Clinical and electrophysiologic observations. Neurology 1992;42(12):2263-6.
Kim HJ, Jeon BS, Lee KW. Hemimasticatory spasm associated with localized scleroderma and facial hemiatrophy. Arch Dermotol 2000;57(4):576-80.
Kim YJ, Lee KS, Na JH, Kim BS, Ko YJ. A case of hemimasticatory spasm. J Korean Neurol Assoc 1994;12(1):175-8.
Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: Comparing different botulinum toxin preparations. Eur J Neurol 2006;13 Suppl 1:21-9.
Laskawi R, Rohrbach S. Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin. Laryngorhinootologie 2001;80(12):708-13.
Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up. Neurology 1999;53(9):2102-7.
Clark GT. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Phys Med Rehabil Clin N Am 2003;14(4):727-48.
FerrÃn LM, Burguera JA, Diago MP, Diago MP. Oromandibular dystonia: A dental approach. Med Oral Patol Oral Cir Bucal 2010;15(1):e25-7.
Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: Long-term management with botulinum toxin. Laryngoscope 2013;123(12):3078-83.
Moore A, Wood G. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin. Br Dent J 1996;183(11-12):415-7.
Ziegler CM, Haag C, Mühling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Investig 2003;7(2):52-5. 85. Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with Type A botulinum toxin. Int J Oral Maxillofac Surg 1997;26(6):458-60.
Fu KY, Chen HM, Sun ZP, Zhang ZK, Ma XC. Long-term efficacy of botulinum toxin Type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg 2010;48(4):281-4.
Bhogal PS, Hutton A, Monaghan A. A review of the current uses of Botox for dentally-related procedures. Dent Update 2006;33(3):165-8.
Bakke M, Møller E, Werdelin LM, Dalager T, Kitai N, Kreiborg S. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100(6):693-700.
Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001;7(4):329-32.
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin Type A for drooling in Parkinson’s disease: A double-blind, randomized, placebo-controlled study. Mov Disord 2006;21(5):704-7.
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004;62(1):37-40.
Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 2004;106(2):93-6.
Fuster Torres MA, Berini Aytés L, Gay Escoda C. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal 2007;12(7):E511-7.
Capaccio P, Torretta S, Osio M, Minorati D, Ottaviani F, Sambataro G, et al. Botulinum toxin therapy: A tempting tool in the management of salivary secretory disorders. Am J Otolaryngol 2008;29(5):333-8.
Svetel M, Vasic M, Dragasevic N, Pekmezovic T, Petrovic I, Kostic V. Botulinum toxin in the treatment of sialorrhea. Vojnosanit Pregl 2009;66(1):9-12.
Benson J, Daugherty KK. Botulinum toxin A in the treatment of sialorrhea. Ann Pharmacother 2007;41(1):79-85.
Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003;61(4):454-7.
Capaccio P, Cuccarini V, Benicchio V, Minorati D, Spadari F, Ottaviani F. Treatment of iatrogenic submandibular sialocele with botulinum toxin. Case report. Br J Oral Maxillofac Surg 2007;45(1):415-7.
Lim YC, Choi EC. Treatment of an acute salivary fistula after parotid surgery: Botulinum toxin Type A injection as primary treatment. Eur Arch Otorhinolaryngol 2008;265(2):243-5.
Corradino B, Di Lorenzo S, Mossuto C, Costa RP, Moschella F. Botulinum toxin in preparation of oral cavity for microsurgical reconstruction. Acta Otolaryngol 2010;130(1):156-60.
Corradino B, Di Lorenzo S, Moschella F. Botulinum toxin A for oral cavity cancer patients: In microsurgical patients BTX injections in major salivary glands temporarily reduce salivary production and the risk of local complications related to saliva stagnation. Toxins (Basel) 2012;4(11):956-61.
Philouze P, Vertu D, Ceruse P. Bilateral gustatory sweating in the submandibular region after bilateral neck dissection successfully treated with botulinum toxin. Br J Oral Maxillofac Surg 2014;52(8):761-3.
Laccourreye O, Akl E, Gutierrez-Fonseca R, Garcia D, Brasnu D, Bonan B. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin Type A: Incidence, management, and outcome. Arch Otolaryngol Head Neck Surg 1999;125(3):283-6.
Guntinas-Lichius O. Increased botulinum toxin Type A dosage is more effective in patients with Freys syndrome. Laryngoscope 2002;112(4):746-9.
Luna Ortiz K, Rascon Ortiz M, Sansón Riofrio JA, Villavicencio Valencia V, Mosqueda Taylor A. Control of Frey’s syndrome in patients treated with botulinum toxin Type A. Med Oral Patol Oral Cir Bucal 2007;12(1):E79-84.
Sonny A, Sunder R, Trikha A. Botulinium toxin in the treatment of Frey’s syndrome: A Brief report. Indian J Anaesth 2008;52:202-4.
Ahuja RB, Chatterjee P. Contemporary solutions for the treatment of facial nerve paralysis. Plast Reconstr Surg 2016;137(2):482e-3.
Garcia RM, Hadlock TA, Klebuc MJ, Simpson RL, Zenn MR, Marcus JR. Contemporary solutions for the treatment of facial nerve paralysis. Plast Reconstr Surg 2015;135(6):1025e-46.
Anthony VB. Asymmetrical smiles corrected by botulinum toxin serotype A. Am Soc Dermatol Surg 2007;33(Sl):S32-6.
Armstrong MW, Mountain RE, Murray JA. Treatment of facial synkinesis and facial asymmetry with botulinum toxin Type A following facial nerve palsy. Clin Otolaryngol Allied Sci 1996;21(1):15-20.
Toffola ED, Furini F, Redaelli C, Prestifilippo E, Bejor M. Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy. Disabil Rehabil 2010;32(17):1414-8.
Montoya FJ, Riddell CE, Caesar R, Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond) 2002;16(6):705-9.
Ellis MF, Daniell M. An evaluation of the safety and efficacy of botulinum toxin Type A (BOTOX) when used to produce a protective ptosis. Clin Exp Ophthalmol 2001;29(6):394-9.
Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin Type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40(6):445-50.
Clark GT, Stiles A, Lockerman LZ, Gross SG. A critical review of the use of botulinum toxin in orofacial pain disorders. Dent Clin N Am 2007;51(1):245-61.
Junghans K, Rohrbach S, Ellies M, Laskawi R. Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application. Head Face Med 2007;3:32.
Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006;142(3):320-6.
Göbel H, Jost WH; Arbeitsgruppe Schmerz im Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft für Neurologie. Botulinum toxin in specific pain therapy. Schmerz 2003;17(7):149-65.
Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, et al. Therapeutic efficacy and safety of botulinum toxin Type A in trigeminal neuralgia: A systematic review. J Headache Pain 2013;14:72.
Guardiani E, Sadoughi B, Blitzer A, Sirois D. A new treatment paradigm for trigeminal neuralgia using botulinum toxin Type A. Laryngoscope 2014;124(2):413-7.
Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: Preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111(1):47-50.
Ngeow WC, Nair R. Injection of botulinum toxin Type A (Botox) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2010;109(3):e47-50.
Akbay E, Cevik C, Damlar I, Altan A. Treatment of displaced mandibular condylar fracture with botulinum toxin A. Auris Nasus Larynx 2014;41(2):219-21.
Canter HI, Kayikcioglu A, Aksu M, Mavili ME. Botulinum toxin in closed treatment of mandibular condylar fracture. Ann Plast Surg 2007;58(5):474-8.
Jeong CH, Ryu JY, Lee WY, Kim HM. Simultaneous surgery for subcondylar fracture and prominent angle of the mandible. Maxillofac Plast Reconstr Surg 2015;37(1):26.
Kayikçioglu A, Erk Y, Mavili E, Vargel I, Ozgür F. Botulinum toxin in the treatment of zygomatic fractures. Plast Reconstr Surg 2003;111(1):341-6.
Zhang DZ, Liu XY, Xiao WL, Xu YX. Botulinum toxin Type A and the prevention of hypertrophic scars on the maxillofacial area and neck: A meta-analysis of randomized controlled trials. PLoS One 2016;11(3):e0151627.
Reddy P, Gosavi D, Reddy S. Lifestyle drugs. Int J Pharm Pharm Sci 2012;4 Suppl 5:43-5.
Ihde S. Utilisation therapeutique de la toxine botulique dans le traitment d’entretien en implantologie dentaire. Implantodontie 2005;14(2):56-61.
Ihde S. Prophylactic use of botulinum toxin in dental implantology. CMF Implement Dir 2007;1:29-34.
Seok H, Park YT, Kim SG, Park YW. Correction of post-traumatic anterior open bite by injection of botulinum toxin Type A into the anterior belly of the digastric muscle: Case report. J Korean Assoc Oral Maxillofac Surg 2013;39(4):188-92.
Chow TL, Chan SW, Lam SH. Ranula successfully treated by botulinum toxin Type A: Report of 3 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:41-2.
Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum
toxin Type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005;53(3):407-15.
Naumann M, Jankovic J. Safety of botulinum toxin Type A: A systematic review and meta-analysis. Curr Med Res Opin 2004;20(7):981-90.
Vidya VS, Felicita AS. Efficacy of pharmacological agents in the treatment of temporomandibular joint disorder: A systematic review. Int J Pharm Pharm Sci 2015;7(4):54-8.
Gok G, Cox N, Bajwa J, Christodoulou D, Moody A, Howlett DC. Ultrasound-guided injection of botulinum toxin A into the submandibular gland in children and young adults with sialorrhoea. Br J Oral Maxillofac Surg 2013;51:231-3.
George KS, Kiani H, Witherow H. Effectiveness of botulinum toxin B in the treatment of drooling. Br J Oral Maxillofac Surg 2013;51(8):783-5.
Alodeani EA. Botulinum toxin Type A: An effective, safe and minimally invasive treatment option of axillary and palmar hyperhidrosis. Int J Pharm Pharm Sci 2016;8(7):237-40.
Mehdizadeh OB, Diels J, White WM. Botulinum toxin in the treatment of facial paralysis. Facial Plast Surg Clin North Am 2016;24(1):11-20.
Benninger B, Ross A. Should dentists be allowed to administer botulinum toxin? Dentistry 2012;2:135.
Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg 2010;39(3):197-207.
Berry MG, Stanek JJ. Botulinum neurotoxin A: A review. J Plast Reconstr Aesthet Surg 2012;65(10):1283-91.
Al Hamdan EM, Algheryafi AM, Al-Ghareeb FJ, Ashri NY. Knowledge and attitude of dentists towards the use of botulinum toxin and dermal fillers in dentistry, Riyadh, Saudi Arabia. J Cosmet Laser Ther 2013;15:46-54.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
